NCT07024680View on ClinicalTrials.gov

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions
Papillary Renal Cell Carcinoma
Interventions
OTHER

Observational, None intervention

Observational, None intervention

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY